Clinical Study on 56-Day Continuous Improvement of 1064nm Fractional Picosecond Laser Treatment With Formulations of A Proprietary Anti-aging Complex Composition

C23021036

This clinical trial aims to learn about the efficacy of MLYAAT-1002® (a proprietary anti-aging complex, MLYAAT is short for "multi-layer anti-ageing technology" ) in female subjects who have newly received the rejuvenation treatment by comparing visual clinical scores, skin attributes measurement and image analysis.

2023-11-18

2024-01-28

2024-02-23

24

Inclusion Criteria: * self-reported facial aging problems such as roughness, fine lines, and dull skin * no symptoms of itching, tingling, or burning on the face * no symptoms of facial flushing, erythema, papules, desquamation, or spot haemorrhage as evaluated by a dermatologist * photodamage scores above 2 (evaluated by a dermatologist) * compliance with split-face use of the assigned formulations for 56 days * no antibiotics remedy in the past three months * regular use of sunscreen products at least five times a week * no plans to leave Shanghai during the period of the trial * compliance with no use of any cosmetics that may bias the study results during the period of the trial * written informed consent and portrait right consent were obtained from all participants before study entry Exclusion Criteria: * female subjects who are pregnant, lactating or planning to become pregnant * history of alcoholism * history of allergies * subjects who have received medical rejuvenation treatment within the past one year * being a participant in any other clinical trial within the past one month * subjects who are suffering from facial skin diseases (melasma, acne, and herpes simplex, etc.) * subjects with scar constitution or that predispose to Koebner's phenomenon (such as vitiligo and lichen planus, etc.) * subjects who had skin diseases (such as psoriasis, eczema, and skin cancer, etc.) * taken/injected anti-allergy medication in the past one month * subjects who had a high fever in the past 2 weeks * received anticancer chemotherapy or immunotherapy in the past 6 months * anyone that the investigator thinks of not eligible.

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 24, 'type': 'ESTIMATED'}}

2024-01-03